Changeflow GovPing Healthcare & Life Sciences Oxadiazole HDAC6 inhibitors and uses thereof
Routine Notice Added Final

Oxadiazole HDAC6 inhibitors and uses thereof

Favicon for changeflow.com USPTO Patent Grants - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO granted Patent US12590084B2 to Eikonizo Therapeutics, Inc. covering oxadiazole compounds that selectively inhibit HDAC6, a protein linked to cancer and neurological disorders including Alzheimer's disease. The patent includes 20 claims and covers pharmaceutical compositions and methods of treating HDAC6-related diseases. Inventors are Florence Fevrier Wagner and Thomas Edward Richardson.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

Eikonizo Therapeutics received USPTO Patent US12590084B2 (Kind B2) for oxadiazole HDAC6 inhibitor compounds, methods of use, and associated pharmaceutical compositions. The patent, filed as Application No. 18132216 on April 7, 2023, and granted March 31, 2026, contains 20 claims under CPC classifications C07D 413/04, C07D 413/14, C07D 471/04, and C07D 487/04. The compounds target HDAC6, a protein implicated in cancer and neurological disorders.

Patent holders should document the grant date and maintain records for enforcement purposes. Competitors developing HDAC6 inhibitors should assess Freedom to Operate implications. No immediate compliance deadlines or regulatory reporting requirements are associated with this patent grant notice.

Archived snapshot

Mar 31, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Oxadiazole HDAC6 inhibitors and uses thereof

Grant US12590084B2 Kind: B2 Mar 31, 2026

Assignee

Eikonizo Therapeutics, Inc.

Inventors

Florence Fevrier Wagner, Thomas Edward Richardson

Abstract

Provided herein are compounds that selectively inhibit HDAC6, a protein whose activity is associated with a variety of diseases (e.g., cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HDAC6-related diseases and disorders (e.g., Alzheimer's disease, cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.

CPC Classifications

C07D 413/04 C07D 413/14 C07D 471/04 C07D 487/04

Filing Date

2023-04-07

Application No.

18132216

Claims

20

View original document →

Named provisions

Oxadiazole HDAC6 inhibitors and uses thereof

Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
March 31st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12590084B2
Docket
18132216

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Patent Grant
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!